Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252780 | 0.89 | PDE4A (0.36) | REN | |
| SCHEMBL21175956 | 0.82 | SLC6A4 (0.37) | KDM4ESLC6A4USP2RENALDH1A1 | |
| SCHEMBL21175808 | 0.81 | SLC6A4 (0.36) | SLC6A4RENALDH1A1KMT2AMEN1 | |
| SCHEMBL19270706 | 0.80 | PDE4A (0.33) | KDM4EALDH1A1 | |
| SCHEMBL19272933 | 0.79 | PDE4B (0.34) | REN | |
| SCHEMBL21175971 | 0.72 | SLC6A4 (0.36) | KDM4ESLC6A4USP2RENALDH1A1 | |
| SCHEMBL18424750 | 0.71 | PDE4B (0.38) | SLC6A4REN | |
| SCHEMBL29613166 | 0.71 | PDE4B (0.38) | SLC6A4REN | |
| SCHEMBL19252786 | 0.71 | LMNA (0.33) | KDM4ESLC6A4USP2ALDH1A1KMT2A | |
| SCHEMBL29613229 | 0.71 | LMNA (0.33) | KDM4ESLC6A4USP2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2019143902-A2 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | KDM4E 1806/4885SLC6A4 4414/4885USP2 3480/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | KDM4E 1806/4885SLC6A4 4414/4885USP2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.